Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

NCT03114683 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
96
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.